Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: efgartigimod PH20 SC Clear all
Completed Phase 2Phase 3 Interventional Results available

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

NCT05267600
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
efgartigimod PH20 SC, placebo, Prednisone
Biological · Other · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Fountain Valley, California • Redwood City, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

NCT04818671
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Carlsbad, California • Palo Alto, California • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 2Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

NCT05523167
View directory record Official record
Conditions
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
EFG PH20 SC, PBO
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Terminated Phase 3 Interventional

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

NCT06307613
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Recruiting No phase listed Observational

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170
View directory record Official record
Conditions
Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
Interventions
Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Carlsbad, California • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Terminated Phase 3 Interventional

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

NCT06307626
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

NCT04687072
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Springdale, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

NCT04735432
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
efgartigimod PH20 SC, efgartigimod IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
14
States / cities
Carlsbad, California • Orange, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

NCT04281472
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Interventions
efgartigimod PH20 SC in stage B, placebo in stage B
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 17, 2026, 4:30 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

NCT06392386
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Charlotte, North Carolina • Denton, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

NCT07570316
View directory record Official record
Conditions
Graves' Disease, Graves Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
27
States / cities
Orange, California • Pasadena, California • San Jose, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Not yet recruiting Phase 2 Interventional

A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults

NCT07583641
View directory record Official record
Conditions
Autoimmune Encephalitis (AE)
Interventions
Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
12 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Tucson, Arizona • Sherman, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

NCT04598477
View directory record Official record
Conditions
Pemphigus Vulgaris, Pemphigus Foliaceus
Interventions
efgartigimod PH20 SC, prednisone
Biological · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 17, 2026, 4:30 PM EDT
Recruiting No phase listed Observational

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

NCT06299748
View directory record Official record
Conditions
Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Efgartigimod
Biological
Lead sponsor
argenx
Industry
Eligibility
Female only
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279
View directory record Official record
Conditions
Myasthenia Gravis, Ocular
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Scottsdale, Arizona • Loma Linda, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT06655155
View directory record Official record
Conditions
Systemic Sclerosis (SSc)
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Plantation, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 4 Interventional

A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

NCT06637072
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Washington D.C., District of Columbia • Maitland, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

NCT04280718
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 17, 2026, 4:30 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

NCT06503731
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

NCT05681481
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
efgartigimod PH20 SC, Prednisone
Biological · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Fountain Valley, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441
View directory record Official record
Conditions
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Beverly Hills, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

NCT04598451
View directory record Official record
Conditions
Pemphigus Vulgaris, Pemphigus Foliaceus
Interventions
efgartigimod PH20 SC, Placebo, prednisone
Biological · Other · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 17, 2026, 4:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847
View directory record Official record
Conditions
Primary Sjogrens Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
42
States / cities
Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Recruiting No phase listed Observational

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

NCT07264426
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 17, 2026, 4:30 PM EDT